at the nexus of biology and chemistry


In many disease areas biology has 
identified the most compelling
drug targets.  The vast majority of
these targets are elusive to drug
discovery for two primary reasons:
1. there are no quality ligands for
the target,  and 2. there is a limited
understanding of the pharmacology
(how hard, how long) required to
effectively modulate the target. 

Our mission starts at the nexus of
target biology and ligand discovery
with two purpose-built platforms:


Chimeric proteins
and chemical genetics to validate and guide target biology and pharmacology

Our biology engine is powered by small molecule control of chimeric proteins, yielding details on the depth and duration of target modulation needed to drive pharmacology.

We use insights from INFINI-T to match target to small molecule modality and guide the optimization of leads by medicinal chemistry toward effective therapeutics for patients. 



>10K covalent fragments
for ligand discovery by
scalable biochemical and in cell proteomics

Our ligand discovery engine is powered by a diverse library of covalent fragments that extends beyond cysteine and can address all ligandable amino acids.

We use protein structure and computation to optimize covalent hits into leads where the small molecule modality is matched to target biology.

the nexo leadership team

Joe Patel
VP, Head of Discovery
Rhamy Zeid
VP, Head of Biology
John Athanasopoulos
VP, Head of Operations
Michael Kim
Chief Operating Officer
Andy Phillips
President, Chief Executive Officer

latest news

Nexo launches chemical biology platform to pursue previously intractable targets  
July 26, 2023 

Nexo Therapeutics today emerged from stealth with a $60 million Series A financing led by founding investor Versant Ventures with participation from New Enterprise Associates and Cormorant Asset Management.  The financing supports Nexo’s platform that combines  combines the power of covalent ligand discovery and chemical biology to unlock a pipeline of novel cancer therapies directed against previously intractable targets. 

Nexo and MD Anderson announce transformative partnership to discover and develop new therapies 
July 26, 2023

Nexo Therapeutics, a biotechnology company dedicated to the discovery and development of novel cancer therapies, and The University of Texas MD Anderson Cancer Center today announced a multi-year strategic collaboration with the goal to produce impactful new cancer therapies for patients with limited treatment options . The agreement brings together Nexo’s unique drug discovery platform with the translational research and drug development expertise of MD Anderson’s Translational Research to AdvanCe Therapeutics and Innovation in ONcology (TRACTION) platform in order to accelerate development of small-molecule therapies in Nexo’s pipeline. 

board of directors

Carlo Rizzuto, Ph. D.
Versant Ventures
Ali Behbahani, M.D.
Andy Phillips
President, Chief Executive Officer
Bihua Chen
Cormorant Asset Management
J.C. Lopez, M.D.

our investors

Corporate Address

11757 W. Ken Caryl Avenue
Suite F, 520
Littleton, CO 80127


65 Grove Street
Suite 102
Watertown, MA 02472

Contact us

[email protected]